Xencor (XNCR) announced the issuance of U.S. Patent 12,492,253, which covers Xencor’s Xtend Fc domain for extending the half-life of antibodies targeting C5, with a term that extends into December 2028. The new patent term is approximately three years longer than the previous latest-to-expire U.S. patent covering the Xtend Fc domain. Xencor now anticipates receiving low-single digit royalties on net sales of Ultomiris, an anti-C5 antibody engineered with a licensed Xtend Fc domain, into December 2028 in the United States. Ultomiris is a drug being developed and commercialized by Alexion Pharmaceuticals, Inc., and is a registered trademark of Alexion. Xencor has also previously secured regulatory extensions of exclusivity in several EU countries, Japan and Australia.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor initiated with a Buy at Truist
- Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target
- Xencor price target raised to $42 from $40 at Cantor Fitzgerald
- Xencor price target lowered to $18 from $20 at JPMorgan
- Xencor Reports Improved Q3 2025 Financial Results